Literature DB >> 2651651

Novobiocin-induced ultrastructural changes and antagonism of DNA synthesis in Trypanosoma cruzi amastigotes growing in cell-free medium.

R L Kerschmann1, J S Wolfson, G L McHugh, G R Dickersin, D C Hooper, M N Swartz.   

Abstract

The antimicrobial agent novobiocin, an inhibitor of the bacterial enzyme topoisomerase II (DNA gyrase), is known to antagonize Trypanosoma cruzi amastigotes growing in cell-free medium. To determine sites of antagonism of novobiocin, the effects of drug on parasite ultrastructure and incorporation of radiolabeled precursors of DNA, RNA and protein into macromolecules were determined. The predominant ultrastructural abnormality seen after exposure to 0.40 mM novobiocin for 24 h was the presence of electron-dense clumps in the mitochondrion-kinetoplast organelle in 95 of 257 (37%) of cells, in comparison to no clumps seen in 110 drug-free cells. In addition, in the nucleus, the karyosome was less distinct than in control cells and appeared to merge with the chromatin. In the radiolabeling studies, incorporation of thymidine was inhibited in a dose-dependent fashion by novobiocin (0.16-0.80 mM) in a range of drug concentrations that also inhibited parasite growth. For 0.16 and 0.24 mM novobiocin, incorporation of thymidine was inhibited up to 65% relative to drug-free control cells while uptake of uridine and leucine was unaltered. We interpret these ultrastructure and precursor-incorporation studies as suggesting that (i) the mitochondrion-kinetoplast and possibly the nucleus are sites of novobiocin antagonism of T. cruzi amastigotes and (ii) that novobiocin appears to antagonize DNA synthesis within these organisms. Whether the drug target is topoisomerase II, however, is as yet unknown.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2651651     DOI: 10.1111/j.1550-7408.1989.tb02669.x

Source DB:  PubMed          Journal:  J Protozool        ISSN: 0022-3921


  4 in total

Review 1.  Opportunistic protozoan infections in human immunodeficiency virus disease: review highlighting diagnostic and therapeutic aspects.

Authors:  A Curry; A J Turner; S Lucas
Journal:  J Clin Pathol       Date:  1991-03       Impact factor: 3.411

2.  In vitro and in vivo activities of 1,3,4-thiadiazole-2-arylhydrazone derivatives of megazol against Trypanosoma cruzi.

Authors:  K Salomão; E M de Souza; S A Carvalho; E F da Silva; C A M Fraga; H S Barbosa; S L de Castro
Journal:  Antimicrob Agents Chemother       Date:  2010-03-15       Impact factor: 5.191

3.  Computer-aided identification of Trypanosoma brucei uridine diphosphate galactose 4'-epimerase inhibitors: toward the development of novel therapies for African sleeping sickness.

Authors:  Jacob D Durrant; Michael D Urbaniak; Michael A J Ferguson; J Andrew McCammon
Journal:  J Med Chem       Date:  2010-07-08       Impact factor: 7.446

4.  High-Throughput Screening of the ReFRAME Library Identifies Potential Drug Repurposing Candidates for Trypanosoma cruzi.

Authors:  Jean A Bernatchez; Emily Chen; Mitchell V Hull; Case W McNamara; James H McKerrow; Jair L Siqueira-Neto
Journal:  Microorganisms       Date:  2020-03-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.